Prospective 2-year study of accelerated pulsed transepithelial corneal crosslinking outcomes for Keratoconus

Abstract

Aims

To report 2-year outcomes of transepithelial, accelerated, pulsed, corneal crosslinking (t-ACXL) for patients with progressive keratoconus.

Methods

Prospective, interventional case series at a university hospital tertiary referral centre. Forty eyes with progressive keratoconus undergoing t-ACXL were included. Treatment was performed with pulsed illumination (1 s on/1 s off) using 45 mW/cm² for 5 min and 20 s, for a surface dose of 7.2 J cm². Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), corneal tomography, anterior segment optical coherence tomography (OCT) and confocal microscopy were evaluated preoperatively and at 12 and 24 months postoperatively.

Results

The mean patient age was 23.32 ± 5.18 years (SD) (range 14–42 years). The mean CDVA significantly improved from 0.38 ± 0.32 logMAR at baseline to 0.30 ± 0.21 logMAR at 24 months (P < 0.01). There was no significant difference in UDVA, MRSE, asymmetry indices, tomographic parameters and endothelial density. The improvement in visual acuity was inversely correlated with preoperative CDVA and preoperative K_Max. No complications were encountered.

Conclusions

In this prospective study, t-ACXL appeared safe and effective in halting progression of keratoconus within a follow-up period of 24 months.

Introduction

Keratoconus is a progressive, non-inflammatory corneal disorder that leads to myopia, irregular astigmatism and reduced visual acuity [1, 2]. Corneal crosslinking (CXL) has rapidly become the treatment of choice to arrest the progression of corneal ectasia since it was first reported in 2003 [3].

CXL has a complex mechanism of action but in brief, it increases the stiffness of the cornea through a photochemical reaction between riboflavin and ultraviolet A (UV-A) in the corneal stroma, which results in the formation of new covalent bonds between collagen fibril amino-acids [4, 5]. Animal studies have shown a 70% increase in corneal rigidity following treatment, and similar human studies have demonstrated a 328% increase in stiffness [3, 6].

The standard CXL protocol, typically referred to as the “Dresden protocol”, was initially reported by Wollensak et al. and requires epithelial removal, application of riboflavin 0.1% solution for 30 min before UV-A exposure, with a wavelength of 370 nm and homogenous irradiance of 3 mW/cm² for 30 min (5.4 J/cm²) [3]. More recent CXL techniques have departed from the original Dresden protocol. These newer techniques use different formulations and delivery methods of riboflavin to avoid epithelial debridement (transepithelial CXL), as well as high-intensity UV-A exposure (accelerated CXL); to shorten duration times, reduce patient discomfort, and minimise postoperative complications such as infection, stromal haze and endothelial toxicity [7].

Accelerated CXL (ACXL) reduces treatment time by taking advantage of the Bunsen–Roscoe law of photochemical reciprocity, which states that the same photochemical effect can be achieved with a reduced irradiation interval provided the total energy level is kept constant through a corresponding increase in irradiation intensity [7]. Experimental data has revealed that the law of photochemical reciprocity is only valid for illumination intensities not exceeding 50 mW/cm² with treatments not lasting longer than 2 min [8]. However, continuous ACXL has been shown to result in lower clinical and experimental efficacy compared to conventional CXL, and this has been attributed to the higher consumption and subsequent shortage of oxygen, and subsequent depletion of reactive oxygen species and oxidation protein products which are key drivers of the crosslinking process in the cornea [9–14]. This led to the development of a pulsed ACXL protocol in which pulsed delivery of the UV-A light is hypothesised to allow more oxygen to diffuse into the corneal stroma and lead to an enhanced release of reactive oxygen species, and thus facilitate a more effective crosslinking process [15].

Previous studies have reported favourable outcomes with both accelerated and transepithelial CXL procedures [16–21], but to the best of the authors’ knowledge, there is no study in the literature reporting long-term outcomes of transepithelial, accelerated, pulsed CXL (t-ACXL) for the treatment of keratoconus. In the present study, we report the 2-year outcomes of t-ACXL for the treatment of patients with documented progressive keratoconus.

Methods

This prospective study enrolled subjects with keratoconus undergoing t-ACXL from August 2014 to October 2015 attending the University of Auckland Cornea and External Eye Disease Service, Greenlane Hospital, Auckland District Health Board, Auckland, New Zealand.

Inclusion criteria included patients with progressive keratoconus that was diagnosed based on clinical and associated tomographic findings. Progressive keratoconus was defined as one or more of the following changes: an increase of 1.00 D or more in the steepest keratometry (K_Max) measurement, an increase of 1.00 D or more in manifest cylinder, or an increase of 0.50 D or more in manifest refraction spherical equivalent (MRSE) over 12 months. The grade of keratoconus was staged according to the Topographic Keratoconus Classification (TKC) system which classifies keratoconus into 5 grades: 0 (normal) to 4 (severe). Exclusion criteria included contraindications to CXL including corneal thickness of <375 µm at the thinnest point, corneal scarring or oedema visible on slit-lamp examination, severe dry eye, prior ocular surgery, trauma, pregnancy or lactation, systemic autoimmune disease and diabetes mellitus. Contact lens wearers were required to remove their contact lens at least 2 weeks before clinical examinations and CXL procedure.

Study examinations were undertaken at baseline, days 3–5 and months 1, 3, 6, 12 and 24 postoperatively. Preoperative and postoperative year 1 and year 2 measurements were used in the analyses of the current study.

The study was approved by the local Health and Disability Ethics Committee, a branch of the Ministry of Health in New Zealand (NTX/08/08/070AM02). Written, informed consent was obtained from all patients after they voiced understanding of the purpose and the procedures of the study in accordance with the Declaration of Helsinki.

Patient assessment

Both eyes of all patients were examined preoperatively and at 1 month, 3 months, 6 months, 12 months and 24 months postoperatively. At each visit, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) were recorded using a logarithm of the minimum angle of resolution (LogMAR) Snellen chart. Patients were also evaluated using slit-lamp biomicroscopy, corneal tomography (Pentacam, Oculus, Germany), in vivo confocal microscopy (Confoscan 4; NIDEK Technology, Italy) and Spectralis anterior segment optical coherence tomography (OCT) imaging (Heidelberg Engineering GmbH, Germany).

Surgical technique

The surgical procedure was conducted under sterile conditions. Two drops of topical proxymetacaine hydrochloride 0.5% (Alcon Laboratories Inc, Fort Worth, TX) were administered and a speculum was placed between the eyelids. The corneal epithelium was left intact and Paracel solution (Avedro, Waltham, MA, USA) containing 0.25% riboflavin-5-phosphate, hydroxypropyl methylcellulose, sodium edetate, trometamol, benzalkonium chloride was applied to the corneal surface every 90 seconds for 4 min. The cornea was then rinsed completely with VibeX Xtra (Avedro) containing 0.25% riboflavin-5-phosphate and NaCl, and the cornea soaked with VibeX Xtra every 90 seconds for 6 min.

Crosslinking was conducted using the Avedro UV-A source (Avedro Inc., Waltham, MS, USA) with 5 min and 20 s of pulsed illumination (1 s on/1 s off) using 45 mW/cm² for a total surface dose of 7.2 J cm². Treated eyes were medicated with ciprofloxacin 0.3% (Alcon Laboratories Inc, Fort Worth, TX) and fluorometholone 0.1% (Santen Pharmaceutical Co, Ltd) eye drops four times a day for 1 week and 1 month, respectively. No contact lens was used.

Statistical analysis

Statistical analysis was performed using SPSS 19.0 for Windows (SPSS, IBM, Chicago, IL, USA). A sample size calculation was performed to distinguish a difference of at least 1.0 D in K_Max between follow-up time points within the same group at a significance level of 0.05, a power of 80% and assumption of a standard deviation of 1.85D. The assumption of the standard deviation was determined from the mean standard deviation of K_Max from the repeatability of K_Max using the Pentacam HR in eyes with keratoconus [22, 23]. This produced a minimum sample size of 29. The distributions of the variables were evaluated by the Kolmogorov–Smirnov test. Paired t-test was used for comparisons. Pearson correlation coefficients were used to analyse the possible correlation between preoperative visual and tomographic parameters and outcomes. A P value < 0.05 was considered significant.

Results

Forty eyes of 40 patients with keratoconus were included in the study. No significant intraoperative/postoperative complications or adverse reactions were observed. Temporary foreign body sensation following CXL was commonly reported in the first 1–3 days after treatment. No patient developed an epithelial defect or clinically significant corneal haze.

Preoperative characteristics of the patients in each treatment group are demonstrated in Table 1. Two patients (5%) were older than 35 years of age at the time of treatment. The mean changes in UDVA and CDVA after t-ACXL are depicted in Fig. 1 and the mean changes in K_Mean and K_Max are demonstrated in Fig. 2. The mean depth of the central demarcation line at 1 month postoperatively as measured on anterior segment OCT examination was 186 ± 19 μm.

Table 1.

Demographics of patients included in the study

Parameters	Value
Patients (n)	40
Age (y)
Mean ± SD	23.32 ± 5.18
Range	14–42
Eye
Right	40%
Left	60%
Keratoconus stage
1–2	10%
2–3	40%
3–4	50%
Contact lens use
No contact lens	45%
RGP	32.5%
Semi-scleral	15%
Soft	7.5%

Fig. 1.

The logMAR UDVA and CDVA after t-ACXL. There was no significant change in logMAR UDVA at any time point after treatment. The CDVA showed no significant change up to the 12 months time point, but showed significant improvement at 24 months compared to baseline (0.38 ± 0.32 at baseline to 0.30 ± 0.21 at 24 months *P ≤ 0.01)

Fig. 2.

The mean change in K_Max and K_Mean following t-ACXL. There was no significant change in K_Max or K_Mean at any time point after t-ACXL

There were no significant differences between the year 1 and baseline and year 2 and baseline regarding mean UDVA, MRSE, K_Mean, K_Max, anterior astigmatism, cornea thinnest point (CTP), asphericity, endothelial cell count and total corneal densitometry. Only one patient (2.5%) showed evidence of progression at the end of the 2-year period, whilst six patients (15%) exhibited a K_Max reduction of ≥1.0 D. Only one patient lost more than two lines of CDVA (2.5%), with 10 patients (25%) gaining two or more lines of CDVA at the final follow-up.

There was also no statistically significant difference in the corneal asymmetry indices; index of surface variance (ISV), index of vertical asymmetry (IVA), keratoconus index (KI), centre keratoconus index (CKI), index of height asymmetry (IHA) and index of height decentration (IHD) following treatment. However, CDVA was significantly improved at the year 2 visit (0.30 ± 0.21 logMAR) compared to the preoperative examination (0.38 ± 0.32 logMAR) (P < 0.01).

The improvement in visual acuity was inversely correlated with preoperative CDVA (r = −0.67, P < 0.01). The improvement in visual acuity was also inversely correlated with the preoperative K_Max (r = −0.52 and P < 0.01).Table 2.

Table 2.

Mean change in visual, refractive and tomographic parameters over 24 months

	Preoperative	12 months	24 months	P1a	P2b
UDVA (logMAR)	0.81 ± 0.40 (0.12–1.58)	0.81 ± 0.40 (0.18–1.60)	0.88 ± 0.41 (0.06–2.08)	0.97	0.08
CDVA (logMAR)	0.38 ± 0.32 (0.12–1.58)	0.32 ± 0.20 (0.18–1.60)	0.30 ± 0.21 (0.06–2.00)	0.12	<0.01
MRSE (D)	−5.32 ± 5.00 (−19.25–1.00)	−5.01 ± 5.47 (−16.25–1.87)	−4.67 ± 5.40 (−16.37–1.25)	0.54	0.19
KMean (D)	50.45 ± 3.99 (44.3–61.5)	50.82 ± 4.05 (44.3–61.3)	50.36 ± 3.87 (44.2–61.6)	0.87	0.93
KMax (D)	59.13 ± 7.40 (46.6–80.7)	60.08 ± 7.24 (48.1–78.6)	58.73 ± 7.13 (47.1–80.6)	0.96	0.78
Anterior astigmatism (D)	4.27 ± 2.44 (0.4–9.0)	4.48 ± 2.24 (0.7–7.9)	4.31 ± 2.19 (1.7–9.8)	0.74	0.98
CTP (um)	419 ± 42 (335–529)	421 ± 48 (305–530)	434 ± 47 (293–538)	0.93	0.21
Asphericity (Q)	−1.02 ± 0.51 (−1.89 to −0.22)	−1.03 ± 0.53 (−1.83 to −0.14)	−1.00 ± 0.52 (−1.95 to −0.26)	0.82	0.96
ISV	97.12 ± 42.58 (25–192)	99.08 ± 39.49 (44–194)	93.68 ± 40.9 (27–175)	0.82	0.70
IVA	0.93 ± 0.50 (0.11–1.77)	0.94 ± 0.49 (0.13–1.72)	0.89 ± 0.46 (0.06–1.70)	0.71	0.68
KI	1.27 ± 0.16 (0.99–1.71)	1.28 ± 0.17 (0.87–1.75)	1.25 ± 0.15 (0.92–1.58)	0.89	0.61
CKI	1.08 ± 0.06 (0.98–1.22)	1.08 ± 0.07 (0.94–1.23)	1.07 ± 0.06 (0.94–1.23)	0.38	0.68
IHA	31.9 ± 25.24 (1.0–101.3)	39.38 ± 25.86 (0.1–93.3)	42.33 ± 36.1 (0–164.2)	0.12	0.20
IHD	0.14 ± 0.08 (0.00–0.34)	0.15 ± 0.08 (0.04–0.33)	0.13 ± 0.08 (0.00–0.33)	0.79	0.82

Significant p-values are given in bold

CTP Cornea thinnest point, ISV index of surface variance, IVA index of vertical asymmetry, KI keratoconus index, CKI center keratoconus index, IHA index of height asymmetry, IHD index of height decentration

^aPaired t-test, comparison of preoperative and year 1 values

^bPaired t-test, comparison of preoperative and year 2 values

Discussion

Keratoconus is a debilitating condition with a disproportionately high impact on public health resources and vision-specific quality of life [24]. CXL has revolutionised the management of keratoconus in recent years by effectively stabilising the underlying ectatic process and in some cases reversing the disease as quantified by key topographic, refractive and visual outcomes [7, 25]. Transepithelial crosslinking is a relatively recent modification to the conventional CXL procedure, which aims to offer numerous advantages by reducing postoperative discomfort, accelerating visual recovery and decreasing the risk of postoperative complications associated with epithelial debridement [26]. It should, however, be noted that the transepithelial procedure does not eliminate the risk of complications such as epithelial sloughing, oedema and diffuse punctate epitheliopathy [27].

Previous studies have demonstrated that in contrast to the conventional procedure, transepithelial crosslinking leads to no detectable increase in collagen fibre diameter [28] and a more limited apoptotic effect on stromal keratocytes [29] suggesting the transepithelial protocol has a more superficial effect on the cornea. There are conflicting reports in the literature regarding the efficacy of transepithelial CXL with some authors reporting stability of the ectatic process after treatment [18, 30], and others reporting progression of the disease entity in a significant proportion of patients [31–33]. There are also conflicting reports regarding the efficacy of transepithelial CXL when compared to epithelium-off CXL with two randomised trials demonstrating superior efficacy of the epithelium-off procedure [34, 35] and one randomised trial reporting similar outcomes between the two treatment modalities [36]. This is unsurprising given the difference in patient populations, disease severity and the diversity of surgical protocols to ensure penetration of the riboflavin with a molecular weight 376 g/mol through the lipophilic cornea and its epithelial tight junctions. These protocols include the use of molecular enhancers such as BAK, ethylenediaminetetraacetic acid or trometamol to loosen epithelial tight junctions and iontophoresis to improve the diffusion of the negatively charged riboflavin molecule through an intact epithelial layer [7].

The inherent technical difficulties associated with the transepithelial procedure led to some questioning the clinical efficacy of this protocol, but a recent meta-analysis has shown no significant difference between transepithelial and conventional crosslinking in visual acuity, flattest keratometry value, steepest keratometry value, spherical equivalent, or endothelial cell density [37]. The meta-analysis did, however, suggest that the transepithelial procedure has a protective influence on corneal thickness but leads to less postoperative corneal flattening compared to conventional crosslinking [37].

Pulsed, accelerated crosslinking is a more novel modification theoretically allowing for a higher stromal oxygen concentration and potential optimisation of the balance between the type II (aerobic) process which typically serves only as a transient and initiating role in the crosslinking process and the type I (anaerobic) photochemical reaction [15]. Pulsed CXL has shown promising preclinical results with porcine corneas crosslinked using the pulsed irradiation proving more resistant to enzymatic digestion than those treated with the continuous irradiation [38]. However, the exact duration of UV-A pulsing is yet to be elucidated as the typical rate of oxygen depletion in a type II photochemical reaction is 15–20 s [15] and physiological tissue oxygen replenishment is only achieved 3 min following discontinuation of UV-A irradiation [39]. This has led to some investigators questioning the efficacy of the current pulsed crosslinking protocols and advocating for an increase in the pulse cycle or a 30–40% increase in UV-A dosage to optimise the crosslinking process [40, 41].

In this study, we analysed the effect of t-ACXL on patients with progressive keratoconus. Our results demonstrate that t-ACXL can effectively halt the progression of the ectatic process as measured by key tomographic indices and deliver a statistically significant improvement in CDVA, after a 24-month follow-up period. We hypothesise that the improvement in CDVA which was not accompanied by a change in MRSE or keratometric parameters, is a result of corneal epithelium remodelling, which leads to a decrease in surface irregularities [42]. We encountered no serious postoperative complications such as corneal haze, oedema, infection or endothelial loss throughout the follow-up period. Pain or foreign body sensation was commonly reported in the first 3 days following t-ACXL but resolved by ten days in all cases.

To our knowledge, there is only one other study reporting on the outcomes of t-ACXL. Tian et al. retrospectively analysed the outcomes of 17 paediatric patients undergoing t-ACXL and reported no statistically significant differences in K_Max, CTP, CDVA or MRSE after 12 months [43]. The results of this small, retrospective study were encouraging with the authors concluding that t-ACXL is a safe treatment for keratoconus which partially prevents disease progression.

Two other studies have reported the outcomes of accelerated but non-pulsed CXL. Aixinjueluo et al. published on 30 eyes undergoing accelerated transepithelial CXL and reported a significant decrease in K_Max, mean keratometry, CTP and a significant improvement in CDVA after a follow-up period of 12 months [44]. Kir et al. published on 48 eyes undergoing accelerated transepithelial CXL and reported no significant changes in MRSE, CDVA and tomographic indices, but did show a significant increase in CTP after 24 months of follow-up [20].

Our results suggest that t-ACXL appears to halt the progression of ectasia in patients with thin corneas and leads to improved CDVA after a period of 2 years, but the procedure does not lead to a flattening effect of the cornea, nor does it increase the corneal thickness at the thinnest point. The demarcation line following CXL, has been proposed to be an indirect indicator of crosslinking efficacy and is in all probability, a clinical manifestation of the depth of CXL, a transition zone between the treated anterior corneal stroma and the untreated posterior layers, that occurs as a result of a change in the stromal refractive index, an increase in collagen fibre diameter, and fibrillar spacing [7]. The mean demarcation line following t-ACXL in this study was 186 ± 19 μm which is similar to other published reports following accelerated transepithelial CXL [44]. The demarcation line following t-ACXL however, appears to be more superficial than other protocols such as conventional CXL (275 μm), accelerated-epithelium-off CXL (279 μm) and transepithelial iontophoresis assisted ACXL (235 μm) [45].

Although prospective in design, our study has a number of potential limitations including a modest sample size, lack of a control group and in vivo morphological evaluation. A large, well-designed randomised controlled trial comparing t-ACXL with other CXL protocols is required to establish its non-inferiority and confirm its superiority in complication profile.

In conclusion, our results suggest that t-ACXL appears to be an effective method of halting the progression of keratoconus over a 24-month follow-up period. This method has the advantages of both accelerated and transepithelial protocols including reduced surgical times, increased patient comfort and a reduced postoperative complication profile. We would, however, advise caution with regards to using this crosslinking protocol routinely and we currently employ this method of CXL in patients with thinner corneas, those who may have difficulty in cooperating with the epithelium-off CXL protocol, and patients who may not adhere to postoperative treatment and follow-up.

Summary

What was known before

• Clinical studies have reported short-term favourable outcomes with both accelerated and transepithelial crosslinking protocols.

What this study adds

• Transepithelial, pulsed, accelerated corneal collagen crosslinking is a safe and effective method for halting the progression of keratoconus over a 24-month follow-up period and leads to an improvement in corrected distance visual acuity.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.